14 results about "Tumor angiogenesis" patented technology

The invention discloses application of a tripterygium wilfordii exosome in preparation of an anti-cervical cancer medicine and a tumor angiogenesis inhibiting medicine, and relates to the field of biological medicine. The medicinal plant exosome derived from tripterygium wilfordii is successfully separated, and it is proved that the medicinal plant exosome can regulate related pathways through delivery of functional nucleic acid molecules to inhibit proliferation and migration of cervical cancer cells and promote active oxygen related apoptosis so as to be used for tumor treatment. The tripterygium wilfordii exosome can further act on vascular endothelial cells in a tumor microenvironment, the migration function of Hela cells is inhibited, and then the effect of resisting cell proliferation in the tumor microenvironment is achieved. The tripterygium wilfordii exosome has the advantages of being simple in preparation method, remarkable in tumor growth resistance and tumor cell migration inhibition effect, good in biocompatibility, high in delivery efficiency and the like, and can be used as a novel nano-drug for tumor treatment.

The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

The invention relates to a construction method of a perfusion vascularized cervical cancer organoid chip, and relates to the technical field of biology. Comprising the following steps: S1, constructing a cervical cancer organ; s2, mixing the cervical cancer organ small cell cluster, the human umbilical vein endothelial cells and the human embryonic lung fibroblasts in proportion, and centrifugally gathering the mixed cells in a low-adsorption U-shaped plate to form a pre-vascularized cervical cancer organ; s3, re-suspending the pre-vascularized cervical cancer organoid and the human umbilical vein endothelial cells in the fibrous protein hydrogel, transferring the pre-vascularized cervical cancer organoid and the human umbilical vein endothelial cells into the organoid chip, and adding a vascularized cervical cancer organoid culture medium for culture, so that the endothelial cells form perfused blood vessels, and finally obtaining the perfused vascularized cervical cancer organoid chip. The prepared perfusion vascularized cervical cancer organoid can well solve the in-vitro vascularization problem of the organoid, simulates the in-vivo tumor angiogenesis process, is close to the in-vivo real tumor microenvironment, and provides technical support for exploration of cervical cancer disease mechanisms and related treatment.

Provided is the use of clostridium ghonii in combination with a tumor angiogenesis inhibitor in the preparation of a pharmaceutical product for treating tumors. Further provided is a drug for treating tumors, and active ingredients of the drug comprise the clostridium ghonii and the tumor angiogenesis inhibitor.

The invention discloses an apatinib-immune synergistic nano-drug based on bacterial source vesicles as well as a preparation method and application of the apatinib-immune synergistic nano-drug. The nano-drug is Apatinib-MVs, and the nano-drug takes a membrane vesicle secreted by parabacteroides coumarini as a carrier to entrap an anti-angiogenesis drug apatinib; in-vitro anti-tumor experiment results show that the nano-drug can exert an efficient anti-tumor effect through a dual synergistic mechanism of inhibiting tumor angiogenesis and activating anti-tumor immune response at the same time.

The invention discloses a cytochalasin compound with an anti-tumor effect as well as a preparation method and application of the cytochalasin compound. The compound disclosed by the invention is derived from a fermentation product of a cynanchum chinense endophytic fungus Aspergilusizukae RD-16. The compound disclosed by the invention has the advantages that the compound can be used for preparing the cynanchum chinense endophytic fungus; the compound has remarkable cytotoxic activity to various tumor cells and almost has no toxicity to normal colonic epithelial cells. Meanwhile, the compound also has an effect of inhibiting angiogenesis. A Western Blot experiment result proves that the compound activates the expression of tumor cell autophagy related protein by inhibiting a PI3K-AKT-mTOR signal channel and induces tumor cells to generate autophagy; on the other hand, by inhibiting expression of angiogenesis related protein p-VEGFR2, tumor angiogenesis is blocked, and the anti-tumor effect is synergistically enhanced through multiple paths. The compound has potential application in preparation of novel anti-tumor drugs, and provides scientific basis for research and development of novel anti-tumor drugs.

In combination with conventional therapies (e.g., targeted therapy, chemotherapy, and angiogenesis inhibitors etc.), immunotherapies targeting checkpoint molecules have shown promise in the treatment of solid or liquid tumors. However, apoptotic regulatory T cells (Treg) induced by such therapies often become more suppressive in the tumor microenvironment (TME), through increased generation of adenosine tightly controlled by ectonucleotidases, viz. CD39 and CD73. CD39 / ENTPD1, a novel checkpoint molecule, is highly expressed and activated on the tumor vasculature and infiltrating immune cells, promoting tumor growth. Deletion or blockade of CD39 enhances anti-tumor activity by augmenting anti-tumor immune responses and inhibiting tumor angiogenesis. The present invention is based at least in part on the development of anti-CD39 antibodies which mediate CD39 downregulation on immune cells, such as T-cells with markers of T-cell exhaustion, and the demonstrated utility of these antibodies in blocking tumor growth with minimal side effects in pre-clinical models.

The invention belongs to the technical field of biological medicine, and relates to application of PARVA as a target spot in lung cancer prevention and treatment. Specifically, the invention provides application of PARVA in preparation of drugs for treating or preventing lung cancer and application of PARVA in reagents or kits for diagnosis or prognosis evaluation of lung cancer. The invention further provides a lung cancer treatment medicine or a lung cancer prevention medicine taking PARVA as a target spot and a kit which comprises a reagent for detecting PARVA mRNA or protein expression and is used for lung cancer diagnosis or lung cancer prognosis evaluation. The invention provides application of PARVA as a target spot in prevention and treatment of lung cancer, and lung cancer cell proliferation, invasion and metastasis and tumor angiogenesis are inhibited by regulating and controlling expression or functions of PARVA in lung cancer cells and tumor microenvironment, so that effective treatment, early diagnosis, recurrence prevention and prognosis evaluation of lung cancer are realized.

The application discloses a kind of tumor angiogenesis simulation methods, including the blood vessel network topology including environment pixel point and blood vessel pixel point generated based on the medical image of patient;Based on the average path length and step length adjustment factor, chemotaxis weight, bifurcation number range and bifurcation probability of related data such as blood vessel tip of blood vessel network topology are constantly updated;And the bifurcation number of each iteration blood vessel tip and the branch length of each branch after bifurcation are calculated based on the update result of each iteration, and the update of blood vessel network topology is completed based on the bifurcation number and the branch length of each branch after bifurcation calculated, constantly circulate until reaching simulation condition.The application quantifies the transport efficiency of blood vessel network by global function index average path length, realizes the evaluation whether blood vessel network presents efficient local characteristics by clustering coefficient and average path length, guarantees that the blood vessel network obtained by simulation is same with real network.

This invention relates to polypeptides, specifically to a PD-1 and αvβ3 bifunctional polypeptide and its applications, the amino acid sequence of which is shown in SEQ ID NO.1. The PD-1 / αvβ3 bifunctional polypeptide can simultaneously inhibit the PD-1 / PD-L1 pathway and the αvβ3 pathway, not only inhibiting tumor growth and invasion and suppressing abnormal tumor angiogenesis, but also promoting immune cell infiltration into tumors by blocking the PD-1 pathway, inhibiting angiogenesis, and regulating PD-L1 expression, thereby modulating the tumor microenvironment and exerting a synergistic immune effect.

The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and / or lysine.

The application discloses an NGR peptide coupled ruthenium complex and a preparation method and application thereof, and belongs to the technical field of tumor photodynamic therapy. The application couples NGR peptide and a two-photon active ruthenium complex to construct a double-targeted photosensitizer. The NGR oligopeptide can specifically combine with CD13 receptors which are highly expressed on the surface of tumor vascular endothelial cells and tumor cells, realize double targeting of'vessel+tumor cell', and significantly improve the tumor enrichment efficiency of drugs. The NGR peptide coupled ruthenium complex provided by the application can efficiently generate active oxygen under the excitation of 820 nm near-infrared light, specifically kill CD13 positive target cells, and the tissue penetration depth can reach 250 microns, which is suitable for deep tumor treatment. Meanwhile, the NGR peptide coupled ruthenium complex can efficiently destroy the pipe forming ability of vascular endothelial cells, and significantly inhibit tumor angiogenesis.

The present disclosure relates to an anti-VEGF-anti-PD-1 multispecific antibody, a pharmaceutical composition of same, and uses thereof. The multispecific antibody may activate the immune system and block tumor angiogenesis simultaneously, thus providing increased antitumor properties.

The present disclosure relates generally to ex vivo primary tumor models prepared from fresh tumor tissues which are useful for screening anti-cancer agents. The fresh tumor tissues are prepared and cultured under suitable conditions to grow an outgrowth of endothelial cells. Killing of these endothelial cells by a candidate agent indicates the efficacy of the agent in inhibiting tumor angiogenesis.